ACC/AHA Guideline Updates
ACC/AHA Guideline Updates
TAVI more prominently featured in latest guideline
When intervention is considered, patients should be evaluated by a Heart Team (Class 1C-EO)
Engagement between the Heart Team and the primary clinical cardiologist is of critical importance
Recommendations for intervention now focus on age and shared decision-making
For symptomatic SAS patients 65 to 80 years old, TAVI should be considered, based on shared
Indications for TAVI are expanding as a result of multiple randomised trials, including the latest PARTNER trials, which are reflected in these recommendations
Patients should be evaluated regularly with examinations and transthoracic echocardiogram (TTE) every year at a minimum
TAVI is now recommended for a large number of patients based on expanded indications.
2020 ACC/AHA guideline on intervention recommendations by age
For symptomatic patients with severe AS and no anatomic contraindication to transfemoral TAVI
Key factors for considering valve intervention for Symptomatic SAS patients have changed
References: 1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020. Epublished DOI: 10.1016/j.jacc.2020.11.018.